Kathie M. Bishop

Acadia Pharmaceuticals (United States) — United States

Medicine · Health Sciences

28h-index9.1kcitations63works6.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neurogenetic and Muscular Disorders Research(26), Genetics and Neurodevelopmental Disorders(19), Autism Spectrum Disorder Research(17), Family and Disability Support Research(12), Nerve injury and regeneration(9)

Publications63 total

Efficacy and Safety of Trofinetide for the Treatment of Rett Syndrome: Results from the Pivotal Phase 3 LAVENDER Study
Neuropediatrics·2025
Trofinetide for the Treatment of Rett Syndrome: Long-Term Safety and Efficacy Results from the Open-Label LILAC and LILAC-2 Studies
Neuropediatrics·2025
Results from the phase 2/3 DAFFODIL study of trofinetide in girls aged 2–4 years with Rett syndrome
Med·2025· 6 citedOpen Access
Gene therapies for neurogenetic disorders
Trends in Molecular Medicine·2025· 11 cited
Assessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Participants in Clinical Trials
Clinical Therapeutics·2025· 1 cited
Population Pharmacokinetic Modeling to Support Trofinetide Dosing for the Treatment of Rett Syndrome
Advances in Therapy·2024· 3 citedOpen Access
Population Pharmacokinetics of Trofinetide in a Pediatric Population Aged 2–4 Years with Rett Syndrome
Advances in Therapy·2024· 1 citedOpen Access
Trofinetide benefits the ability to communicate in Rett syndrome: a plain language summary of the LAVENDER trial
Future Rare Diseases·2024Open Access
Physiologically-Based Pharmacokinetic Modeling of Trofinetide in Moderate Renal Impairment for Phase 1 Clinical Study Dose Selection with Model Validation
European Journal of Drug Metabolism and Pharmacokinetics·2024· 2 citedOpen Access
Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study
Med·2024· 15 citedOpen Access
Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study
Med·2024· 26 citedOpen Access
Assessing Experiences with Trofinetide for Rett Syndrome: Interviews with Caregivers of Patients in Open-label Studies (S37.008)
Neurology·2024· 1 cited
Exposure–Response Efficacy Modeling to Support Trofinetide Dosing in Individuals with Rett Syndrome
Advances in Therapy·2024· 8 citedOpen Access
Development of trofinetide for the treatment of Rett syndrome: from bench to bedside
Frontiers in Pharmacology·2024· 17 citedOpen Access
Trofinetide Treatment Demonstrates a Benefit Over Placebo for the Ability to Communicate in Rett Syndrome
Pediatric Neurology·2023· 25 citedOpen Access
A Plain Language Summary of Results from the LAVENDER Study: Trofinetide Treatment for Rett Syndrome
Future Rare Diseases·2023Open Access
Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study
Nature Medicine·2023· 173 citedOpen Access
Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial
The Lancet Neurology·2023· 49 cited
Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study
The Lancet Child & Adolescent Health·2021· 100 cited
Autopsy Analyses in Neurological Drug Development—Opening the Black Box
JAMA Neurology·2019· 1 cited
page 1 of 4Next →

Frequent Co-authors

Jacqueline Montes(17), Darryl C. De Vivo(16), Claudia A. Chiriboga(13), Daniel A. Norris(13), Richard S. Finkel(12), C. Frank Bennett(12), Basil T. Darras(11), John Day(9), K. Alexander(9), Raymond T. Bartus(9), James M. Youakim(9), Eugene Schneider(8), Susan T. Iannaccone(7), Kathryn J. Swoboda(7), Frank Bennett(7), Wildon Farwell(6), Christopher D. Herzog(6), Jeffrey L. Neul(6), Alan K. Percy(6), Mehdi Gasmi(6)